{'fraction_non_alphanumeric': 0.029217719132893498, 'fraction_numerical': 0.027332704995287466, 'mean_word_length': 5.174418604651163, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
UNDIFFERENTIATED ENDOMETRIAL CANCER, A DIFFERENT ENTITY WITH AN AGGRESSIVE BEHAVIOR: IGCS-0060 Uterine Cancer, including Sarcoma

Results: We identified 22 patients with the diagnosis of undifferentiated endometrial cancer. Medium age was 65 years. Obesity was common, with medium body mass index of 30. Slightly over half (12/22) were diagnosed at stage III or IV. Common metastatic sites were nodal (9/12 patients), hematogenous (6) and intraperitoneal (6). Just 4/12 patients were fit enough to undergo treatment for metastatic disease. None responded to platinum based chemotherapy given as first line treatment or to Doxorubicin as second line treatment, and in fact developed rapidly progressive disease. External beam radiation was used in 2 patients with metastatic disease: one had stable disease within the radiation fields region but developed distant disease within 2 months, the second patient had progressive disease within the radiation fields. Overall survival was 14 months for all patients, and 6 months for patients with stage 3 or 4 disease.